key: cord-0994465-5x7863q5 authors: Payandeh, Mehrdad; Habibi, Reza; Norooznezhad, Amir Hossein; Hoseinkhani, Zohreh; Mansouri, Feizollah; Yarani, Reza; Thakor, Avnesh S.; Bakhtiari, Mitra; Esmailli, Farzaneh; Mansouri, Kamran title: Human Placenta-derived Mesenchymal Stromal Cells Transfusion in a Critically Ill Infant Diagnosed with Coronavirus Disease 2019 (COVID-19): A Case Report date: 2022-05-10 journal: Transfus Apher Sci DOI: 10.1016/j.transci.2022.103454 sha: acb8269ae271c62ed32e42f65395b158ebe76878 doc_id: 994465 cord_uid: 5x7863q5 Coronavirus disease 2019 (COVID-19) is still an emergency in many countries. Herein, we report treatment with human placental-derived mesenchymal stromal cells transfusion (hPD-MSCT) in a critically ill infant diagnosed with COVID-19. A 28-day-old male infant with a history of pneumonia was referred to our center with decreased SpO(2) (92%) and fever (38.5°C). Real-time reverse transcription polymerase chain reaction (RT-PCR) and chest computed tomography (CT) confirmed COVID-19 infection. Considering the deteriorating clinical status of the patient despite the routine treatments (SpO(2) 82%), human placental derived mesenchymal stromal cells (hPD-MSCs) was transfused to him on day 9 and 11 (7 × 10(6) cells/session). The patient’s general condition started to change 3 days after hPD-MSCT and poor feeding and low SpO(2) improved day by day. On day 20, the patient was discharged (SpO(2) 97%) and our one-year follow-up showed a successful response to the treatment with no reported complications. hPD-MSCT may be considered as a possible treatment option in infants/children diagnosed with COVID-19 who fail to respond to conventional therapies. However, required dose, safety, and mechanistic studies are still warranted to further investigate this treatment. Coronavirus disease 2019 (COVID-19) which causes by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been spread all over the world and has led to a pandemic emergency [1] . The most prominent sign of this disease has been mentioned as pneumonia [2] , J o u r n a l P r e -p r o o f 3 however, other organ(s) dysfunction/failure has been reported especially in critically ill patients [3] . One of the most important pathways in the pathogenesis of COVID-19 in critically ill patients is cytokine storm which is the result of excess pro-inflammatory cytokines release [2] . Acute respiratory distress syndrome (ARDS) is among the most important concerns in COVID-19. Different pathways have been suggested for ARDS which among them is inflammation, especially cytokine storm has been known to has a solid role [4] . Thus, suppression of inflammation and related pathways have been suggested as one of the most important treatment options in critically ill patients diagnosed with COVID-19 [5] . This report highlights the successful treatment with allogeneic human placental-derived mesenchymal stromal cells transfusion (hPD-MSCT) in a 1-month-old male patient with a history of previous pneumonia and a current diagnosis of severe COVID-19 accompanied with a long follow-up period. Mesenchymal stromal cells (MSCs) derived from human placenta tissue (single donor) were isolated and identified as previously has been fully described by our team [6] . Our hospital received the transfer of a 28-day-old infant who was born from a singleton term pregnancy by cesarean delivery from a healthy mother with no underlying condition, other than well-controlled pregnancy hypothyroidism. The neonate was referred given the complicated course he underwent after birth with admission to the neonatal intensive care unit (NICU) with the diagnosis of severe neonatal asphyxia which progressed to fever and a productive cough. On arrival, the infant was moderately dehydrated with a respiratory rate of 55 breaths per minute and SpO 2 of 92% (details in Table 1 ). Given these findings, he was admitted to the intensive care unit where noninvasive O 2 therapy was started (FiO 2 : 21-40%, 6-8 liters O 2 per minute). Table 1 ) as well as laboratory variables ( Table 2 ) of the patient he was discharged on HD 20. Also, a new chest X-ray was performed a week after the discharge day which showed resolution of the central opacification ( Figure 1C) . In this case, we have performed a 250-day follow-up which showed no adverse effect related to hPD-MSCT or any sign/symptom in favor of respiratory issues. This follow-up is still ongoing for at least one year for any side effects regarding the treatment. J o u r n a l P r e -p r o o f 6 In this report, a 30-day male infant that had an unknown history of pneumonia (to us at admission) with further confirmed SARS-CoV-2 infection was successfully treated with hPD-MSCs. The patient's clinical status has been improved following the intervention. Not only the clinical manifestations ( Table 1 ) but also laboratory variables have been improved following the intervention ( Table 2) . Recently, few studies have evaluated the outcome of allogeneic MSCs infusion for patients with COVID-19. Liang et al. [7] , have reported a successful intervention in a critically ill 65-year-old woman who did not respond to the regular treatments in 12 days. Three sessions of human umbilical cord mesenchymal stromal cell transplantation (hUCMSCT) with 5 × 10 7 cells/session were administered for her with an interval of 3 days. On the HD 30, the patient was discharged. Unfortunately, no further follow-up was reported by the authors [7] . Another study by Shu et al., on 12 patients diagnosed with COVID-19 was performed with an endpoint of 14 days. They have shown that the hUCMSCT reduced IL-6 and CRP levels as well as improved lung inflammation compared to the control group. Also, significant clinical improvement was observed on HD 7 and all of the patients of the intervention group were discharged [8] . One of the main important differences between the mentioned study and the current report is the previous pneumonia of the patient. However, other bolded differences such as the age of the patient and the source of MSCs are among the important differences with other reports. MSCs have been used in the clinic for many years to treat different inflammatory diseases such as systemic lupus erythematosus (SLE) [9] and graft-versus-host disease [10] . In a recent (2020) systematic review and meta-analysis, the authors have shown that both autologous and allogeneic MSCs with different sources are safe to be used in the clinic [11] . The immunomodulation effect of the MSCs has been reported to be from the regulation of different J o u r n a l P r e -p r o o f 7 immune system cells responsible for inflammation. MSCs promote the survival of monocytes and induce differentiation toward macrophage M2 anti-inflammatory phenotype that expresses CD 206 and CD 163. Also, activated MSCs secrete prostaglandin E2 that drives resident macrophages with an M1 pro-inflammatory phenotype toward an M2 anti-inflammatory phenotype. Also, MSCs exert their immune suppressive potential through cell-cell contact and by secretion of immune regulatory molecules [12] [13] [14] . MSCs display broad immunomodulatory properties including affecting the proliferation and function of T cells, Natural killer T cells, T regulatory cells B cells, and dendritic cells. However, several soluble factors have been shown to play a major role in the immunosuppressive effects of MSCs, including prostaglandin E2, transforming growth factor β1, indoleamine 2,3-dioxygenase, nitric oxide, hepatocyte growth factor, and IL-10 [12, 13] . Also, the antimicrobial role of MSCs has been reported [15] which could be effective for those COVID-19 patients with secondary bacterial infections such as hospital-acquired infections, especially in intubated patients. According to our knowledge, this is the first report on an infant who received hPD-MSCs for COVID-19. The patient was in the critically ill stage of the disease and didn't respond to the conventional treatments. As we know so far, hPD-MSCs just have been used in the trials/case series/case reports but further dosage investigation for each disease/disorder, its safety, and mechanistic studies are still warranted to further clinical administration. Authors declare no conflict of interests. Primary Symptoms, Comorbidities, and Outcomes of 431 Hospitalized Patients with Confirmative RT-PCR Results for COVID-19 Possible Cause of Inflammatory Storm and Septic Shock in Patients Diagnosed with Coronavirus-19 Disease (COVID-19) Extrapulmonary manifestations of COVID-19 How COVID-19 induces cytokine storm with high mortality Cytokine storm intervention in the early stages of COVID-19 pneumonia Human placental mesenchymal stromal cell-derived exosome-enriched extracellular vesicles for chronic cutaneous graft-versus-host disease: A case report Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis Isolation and expansion of mesenchymal stem/stromal cells derived from human placenta tissue Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases Immune modulation by mesenchymal stem cells Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use The authors are grateful for the kind permission of patients' legal guardians for publishing the data. Also, we thank Dr. Parisa Karami for her kind comments.